Literature DB >> 28528523

Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling.

Anthony J Hatswell1,2, Fleur Chandler3,4.   

Abstract

Keywords:  Chronic Obstructive Pulmonary Disease; Multiple Myeloma; Muscular Dystrophy; Psoriasis; Vemurafenib

Mesh：

Year:  2017        PMID： 28528523     DOI： 10.1007/s40273-017-0516-2

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  7 in total

1.  Time for cooperation in health economics among the modelling community.

Authors:  Renée J G Arnold; Sean Ekins
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Addressing the challenge for well informed and consistent reimbursement decisions: the case for reference models.

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon
Journal:  Pharmacoeconomics       Date:  2011-10       Impact factor: 4.981

3.  Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma.

Authors:  D Lee; J Porter; N Hertel; A J Hatswell; A Briggs
Journal:  BioDrugs       Date:  2016-08       Impact factor: 5.807

4.  The International Burden of Migraine Study (IBMS): study design, methodology, and baseline cohort characteristics.

Authors:  Krista A Payne; Sepideh F Varon; Ariane K Kawata; Karen Yeomans; Teresa K Wilcox; Aubrey Manack; Dawn C Buse; Richard B Lipton; Peter J Goadsby; Andrew M Blumenfeld
Journal:  Cephalalgia       Date:  2011-06-20       Impact factor: 6.292

5.  The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.

Authors:  Andrew J Palmer; Stéphane Roze; William J Valentine; Michael E Minshall; Volker Foos; Francesco M Lurati; Morten Lammert; Giatgen A Spinas
Journal:  Curr Med Res Opin       Date:  2004-08       Impact factor: 2.580

6.  Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

Authors:  Jim Chilcott; Chris McCabe; Paul Tappenden; Anthony O'Hagan; Nicola J Cooper; Keith Abrams; Karl Claxton; David H Miller
Journal:  BMJ       Date:  2003-03-08

Review 7.  Economic evaluation in chronic pain: a systematic review and de novo flexible economic model.

Authors:  W Sullivan; M Hirst; S Beard; D Gladwell; F Fagnani; J López Bastida; C Phillips; W C N Dunlop
Journal:  Eur J Health Econ       Date:  2015-09-16
  7 in total
  3 in total

1.  Ahead of Our Time: Collaboration in Modeling Then and Now.

Authors:  Renée J G Arnold; Sean Ekins
Journal:  Pharmacoeconomics       Date:  2017-09       Impact factor: 4.981

Review 2.  Transparency in Decision Modelling: What, Why, Who and How?

Authors:  Christopher James Sampson; Renée Arnold; Stirling Bryan; Philip Clarke; Sean Ekins; Anthony Hatswell; Neil Hawkins; Sue Langham; Deborah Marshall; Mohsen Sadatsafavi; Will Sullivan; Edward C F Wilson; Tim Wrightson
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

3.  Life Expectancy in Duchenne Muscular Dystrophy: Reproduced Individual Patient Data Meta-analysis.

Authors:  Jonathan Broomfield; Micki Hill; Michela Guglieri; Michael Crowther; Keith Abrams
Journal:  Neurology       Date:  2021-10-13       Impact factor: 9.910
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.